Insider · CIK 0001754154

Giacobello Scott M.

Reports to the SEC for 2 companies · MORRISTOWN, NJ

sec.gov

Transactions

Companies

Filings

CIK

0001754154

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-15	WHWKWhitehawk Therapeutics, Inc. · Stock Option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+118K sh	—	—	118,476
2026-09-15	WHWKWhitehawk Therapeutics, Inc. · Restricted Stock UnitsA Award	CHIEF FINANCIAL OFFICER	AAward	+118K sh	—	—	118,476
2026-09-15	WHWKWhitehawk Therapeutics, Inc. · Stock Option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+118K sh	—	—	118,476
2026-09-15	WHWKWhitehawk Therapeutics, Inc. · Restricted Stock UnitsA Award	CHIEF FINANCIAL OFFICER	AAward	+118K sh	—	—	118,476
2026-05-14	WHWKWhitehawk Therapeutics, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+38.3K sh	$3.92	+$150K	333,489
2026-04-16	WHWKWhitehawk Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−142K sh	$4.13	−$585K	295,224
2026-04-15	WHWKWhitehawk Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−77K sh	$3.86	−$297K	436,824
2026-04-01	WHWKWhitehawk Therapeutics, Inc.M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	+474K sh	—	—	502,002
2026-04-01	WHWKWhitehawk Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	−474K sh	—	—	0
2026-04-01	WHWKWhitehawk Therapeutics, Inc. · Stock Option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+301K sh	—	—	300,677
2026-03-02	WHWKWhitehawk Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−2,594 sh	$3.31	−$8,585.102	28,100
2026-03-01	WHWKWhitehawk Therapeutics, Inc.M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	+6,750 sh	—	—	30,694
2026-03-01	WHWKWhitehawk Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	−6,750 sh	—	—	13,500
2025-04-01	WHWKWhitehawk Therapeutics, Inc. · Stock Option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+474K sh	—	—	473,902
2025-04-01	WHWKWhitehawk Therapeutics, Inc. · Restricted Stock UnitsA Award	CHIEF FINANCIAL OFFICER	AAward	+474K sh	—	—	473,902
2025-03-03	WHWKWhitehawk Therapeutics, Inc.S Sale	CHIEF FINANCIAL OFFICER	SSale	−2,806 sh	$2.35	−$6,594.1	23,944
2025-03-01	WHWKWhitehawk Therapeutics, Inc.M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	+6,750 sh	—	—	26,750
2025-03-01	WHWKWhitehawk Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	−6,750 sh	—	—	20,250
2024-03-01	WHWKWhitehawk Therapeutics, Inc. · Stock Option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+138K sh	—	—	138,263
2024-03-01	WHWKWhitehawk Therapeutics, Inc. · Stock Option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+55K sh	—	—	55,000
2024-03-01	WHWKWhitehawk Therapeutics, Inc. · Restricted Stock UnitsA Award	CHIEF FINANCIAL OFFICER	AAward	+27K sh	—	—	27,000
2023-04-03	WHWKWhitehawk Therapeutics, Inc. · Stock Option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+100K sh	—	—	100,000
2023-03-01	WHWKWhitehawk Therapeutics, Inc. · Stock option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+90K sh	—	—	90,000
2022-09-26	WHWKWhitehawk Therapeutics, Inc.A Award	CHIEF FINANCIAL OFFICER	AAward	+20K sh	$12.50	+$250K	20,000
2022-04-01	WHWKWhitehawk Therapeutics, Inc. · Stock option (right to buy)A Award	CHIEF FINANCIAL OFFICER	AAward	+46.4K sh	—	—	46,400
2021-05-05	GW PHARMACEUTICALS PLCShare OptionsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−68.5K sh	—	—	0
2021-05-05	GW PHARMACEUTICALS PLCD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−165K sh	—	—	0
2021-05-05	GW PHARMACEUTICALS PLCShare OptionsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−44.2K sh	—	—	0
2021-05-05	GW PHARMACEUTICALS PLCShare OptionsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−67.2K sh	—	—	0
2021-05-05	GW PHARMACEUTICALS PLCShare OptionsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−70.1K sh	—	—	0
2021-05-05	GW PHARMACEUTICALS PLCShare OptionsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−43.8K sh	—	—	0
2021-05-05	GW PHARMACEUTICALS PLCShare OptionsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−86.9K sh	—	—	0
2021-05-05	GW PHARMACEUTICALS PLCShare OptionsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−145K sh	—	—	0
2021-05-05	GW PHARMACEUTICALS PLCShare OptionsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−12.6K sh	—	—	0
2021-05-05	GW PHARMACEUTICALS PLCShare OptionsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−83.8K sh	—	—	0
2021-05-05	GW PHARMACEUTICALS PLCShare OptionsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−10.4K sh	—	—	0
2021-05-05	GW PHARMACEUTICALS PLCShare OptionsD Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−8,136 sh	—	—	0
2021-03-02	GW PHARMACEUTICALS PLCShare OptionsA Award	Chief Financial Officer	AAward	+43.8K sh	—	—	43,824
2021-03-02	GW PHARMACEUTICALS PLCShare OptionsA Award	Chief Financial Officer	AAward	+70.1K sh	—	—	70,092
2021-03-01	GW PHARMACEUTICALS PLCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+6,288 sh	$0.00	+$8.803	168,408
2021-03-01	GW PHARMACEUTICALS PLCShare OptionsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−6,288 sh	—	—	0
2021-03-01	GW PHARMACEUTICALS PLCF Tax Payment	Chief Financial Officer	FTax Payment	−3,300 sh	$17.85	−$58.9K	165,108
2021-02-26	GW PHARMACEUTICALS PLCF Tax Payment	Chief Financial Officer	FTax Payment	−72.6K sh	$17.90	−$1.3M	157,163
2021-02-26	GW PHARMACEUTICALS PLCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+139K sh	$0.00	+$194.258	229,812
2021-02-26	GW PHARMACEUTICALS PLCM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+10.4K sh	$0.00	+$14.566	167,567
2021-02-26	GW PHARMACEUTICALS PLCF Tax Payment	Chief Financial Officer	FTax Payment	−5,447 sh	$17.90	−$97.5K	161,120
2021-02-26	GW PHARMACEUTICALS PLCShare OptionsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−139K sh	—	—	0
2021-02-26	GW PHARMACEUTICALS PLCShare OptionsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−10.4K sh	—	—	0
2021-02-22	GW PHARMACEUTICALS PLCShare OptionsA Award	Chief Financial Officer	AAward	+70.1K sh	—	—	70,128
2021-02-22	GW PHARMACEUTICALS PLCShare OptionsA Award	Chief Financial Officer	AAward	+43.8K sh	—	—	43,812

Recent filings

Accepted (ET)
Sep 184/A
Giacobello Scott M.0001754154-26-000016
SEC(opens sec.gov)
Sep 154
Giacobello Scott M.0001754154-26-000014
SEC(opens sec.gov)
May 184
Giacobello Scott M.0001754154-26-000012
SEC(opens sec.gov)
Apr 174
Giacobello Scott M.0001754154-26-000010
SEC(opens sec.gov)
Apr 34
Giacobello Scott M.0001754154-26-000005
SEC(opens sec.gov)
Mar 104
Giacobello Scott M.0001754154-26-000002
SEC(opens sec.gov)
Apr 34
Giacobello Scott M.0001415889-25-010079
SEC(opens sec.gov)
Mar 34
Giacobello Scott M.0001415889-25-006318
SEC(opens sec.gov)
Mar 44
Giacobello Scott M.0001415889-24-006411
SEC(opens sec.gov)

Companies

Address

C/O WHITEHAWK THERAPEUTICS, INC. 2 HEADQUARTERS PLAZA, EAST BUILDING, 11T

MORRISTOWN, NJ, 07960